ATE349208T1 - Phytoestrogene und probiotikum für die weibliche gesundheit - Google Patents
Phytoestrogene und probiotikum für die weibliche gesundheitInfo
- Publication number
- ATE349208T1 ATE349208T1 AT04012697T AT04012697T ATE349208T1 AT E349208 T1 ATE349208 T1 AT E349208T1 AT 04012697 T AT04012697 T AT 04012697T AT 04012697 T AT04012697 T AT 04012697T AT E349208 T1 ATE349208 T1 AT E349208T1
- Authority
- AT
- Austria
- Prior art keywords
- body weight
- sis
- group
- bone
- ovariectomised
- Prior art date
Links
- 239000003075 phytoestrogen Substances 0.000 title 1
- 239000006041 probiotic Substances 0.000 title 1
- 235000018291 probiotics Nutrition 0.000 title 1
- 230000037396 body weight Effects 0.000 abstract 13
- 235000003687 soy isoflavones Nutrition 0.000 abstract 12
- 210000000988 bone and bone Anatomy 0.000 abstract 10
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 5
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 abstract 5
- 239000011575 calcium Substances 0.000 abstract 5
- 229910052791 calcium Inorganic materials 0.000 abstract 5
- 239000011574 phosphorus Substances 0.000 abstract 5
- 229910052698 phosphorus Inorganic materials 0.000 abstract 5
- 241001465754 Metazoa Species 0.000 abstract 4
- 230000000694 effects Effects 0.000 abstract 4
- 210000000689 upper leg Anatomy 0.000 abstract 4
- 210000004291 uterus Anatomy 0.000 abstract 4
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N Daidzein Natural products C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 abstract 3
- GMTUGPYJRUMVTC-UHFFFAOYSA-N Daidzin Natural products OC(COc1ccc2C(=O)C(=COc2c1)c3ccc(O)cc3)C(O)C(O)C(O)C=O GMTUGPYJRUMVTC-UHFFFAOYSA-N 0.000 abstract 3
- KYQZWONCHDNPDP-UHFFFAOYSA-N Daidzoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-UHFFFAOYSA-N 0.000 abstract 3
- ZCOLJUOHXJRHDI-FZHKGVQDSA-N Genistein 7-O-glucoside Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)c1cc(O)c2C(=O)C(c3ccc(O)cc3)=COc2c1 ZCOLJUOHXJRHDI-FZHKGVQDSA-N 0.000 abstract 3
- CJPNHKPXZYYCME-UHFFFAOYSA-N Genistin Natural products OCC1OC(Oc2ccc(O)c3OC(=CC(=O)c23)c4ccc(O)cc4)C(O)C(O)C1O CJPNHKPXZYYCME-UHFFFAOYSA-N 0.000 abstract 3
- YCUNGEJJOMKCGZ-UHFFFAOYSA-N Pallidiflorin Natural products C1=CC(OC)=CC=C1C1=COC2=CC=CC(O)=C2C1=O YCUNGEJJOMKCGZ-UHFFFAOYSA-N 0.000 abstract 3
- KYQZWONCHDNPDP-QNDFHXLGSA-N daidzein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 KYQZWONCHDNPDP-QNDFHXLGSA-N 0.000 abstract 3
- ZCOLJUOHXJRHDI-CMWLGVBASA-N genistein 7-O-beta-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C(C=3C=CC(O)=CC=3)=COC2=C1 ZCOLJUOHXJRHDI-CMWLGVBASA-N 0.000 abstract 3
- 241000195955 Equisetum hyemale Species 0.000 abstract 2
- 241000700159 Rattus Species 0.000 abstract 2
- 230000001195 anabolic effect Effects 0.000 abstract 2
- 239000000262 estrogen Substances 0.000 abstract 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 abstract 2
- 238000009806 oophorectomy Methods 0.000 abstract 2
- 230000008092 positive effect Effects 0.000 abstract 2
- 230000000638 stimulation Effects 0.000 abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 2
- 206010002091 Anaesthesia Diseases 0.000 abstract 1
- 241000894006 Bacteria Species 0.000 abstract 1
- 244000085625 Equisetum Species 0.000 abstract 1
- 206010030247 Oestrogen deficiency Diseases 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 230000037005 anaesthesia Effects 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000008859 change Effects 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 abstract 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 1
- 230000006872 improvement Effects 0.000 abstract 1
- 230000000968 intestinal effect Effects 0.000 abstract 1
- 235000014655 lactic acid Nutrition 0.000 abstract 1
- 239000004310 lactic acid Substances 0.000 abstract 1
- 229940066544 lactobacillus sporogenes Drugs 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000000529 probiotic effect Effects 0.000 abstract 1
- 229910052710 silicon Inorganic materials 0.000 abstract 1
- 239000010703 silicon Substances 0.000 abstract 1
- 210000004872 soft tissue Anatomy 0.000 abstract 1
- 238000012453 sprague-dawley rat model Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Zoology (AREA)
- Alternative & Traditional Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/448,405 US7025998B2 (en) | 2003-05-30 | 2003-05-30 | Phytoestrogens and probiotic for women's health |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE349208T1 true ATE349208T1 (de) | 2007-01-15 |
Family
ID=33131610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04012697T ATE349208T1 (de) | 2003-05-30 | 2004-05-28 | Phytoestrogene und probiotikum für die weibliche gesundheit |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7025998B2 (de) |
| EP (1) | EP1481676B1 (de) |
| AT (1) | ATE349208T1 (de) |
| DE (1) | DE602004003859T2 (de) |
| ES (1) | ES2279995T3 (de) |
| PT (1) | PT1481676E (de) |
| TW (1) | TW200616653A (de) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2492754C (en) | 2002-07-24 | 2018-05-22 | Children's Hospital Medical Center | Compositions and products containing enantiomeric equol, and methods for their making |
| CN101039688A (zh) * | 2004-08-18 | 2007-09-19 | 生物健康解决方案股份有限公司 | 用于预防或治疗尿失禁和膀胱过度活跃的草药组合物 |
| MX2007007731A (es) * | 2004-12-24 | 2007-10-18 | Dolphst Pty Ltd | Formulaciones y tratamientos para el bienestar. |
| MXPA05008573A (es) * | 2005-08-12 | 2007-02-12 | Leopoldo Espinosa Abdala | Composicion de isoflavonas para tratamiento de los sintomas y trastornos fisiologicos de la menopausia. |
| NL1031399C2 (nl) * | 2006-03-17 | 2007-09-18 | Biohorma B V | Samenstelling voor het voorkomen, verminderen of behandelen van verlies van botdichtheid. |
| EP2133080A1 (de) | 2008-06-13 | 2009-12-16 | Haelan Schweiz GmbH | Zusammensetzungen enthaltend Equol |
| WO2010027344A1 (en) * | 2008-09-04 | 2010-03-11 | Om Pharma | Immunomodulatory extracts from lactobacillus bacteria and methods of manufacturing and use thereof |
| US20100055082A1 (en) * | 2008-09-04 | 2010-03-04 | Jacques Alain Bauer | Immunomodulatory extracts from lactobacillus bacteria and methods of manufacturing and use thereof |
| IT1392101B1 (it) * | 2008-12-12 | 2012-02-09 | Zuccari Societa A Responsabilita Limitata In Breve Zuccari S R L | Composizione comprendente isoflavoni |
| US8735374B2 (en) * | 2009-07-31 | 2014-05-27 | Intelgenx Corp. | Oral mucoadhesive dosage form |
| US20110136815A1 (en) * | 2009-12-08 | 2011-06-09 | Horst Zerbe | Solid oral film dosage forms and methods for making same |
| US10610528B2 (en) | 2009-12-08 | 2020-04-07 | Intelgenx Corp. | Solid oral film dosage forms and methods for making same |
| WO2011113965A1 (es) * | 2010-03-18 | 2011-09-22 | Farmalider, S.A. | Composición farmacéutica en forma sólida que contiene isoflavonas, una sal de calcio y vitamina d3 |
| FR2980670B1 (fr) * | 2011-09-30 | 2013-11-01 | Ethno Prospections E | Specialite micronutritionnelle a base de roches sedimentaires et de vegetaux |
| BR112016031000B1 (pt) | 2014-07-01 | 2022-01-25 | Probi USA, Inc. | Forma de dosagem em camadas e método para fazer a mesma |
| CN107095971A (zh) * | 2016-02-19 | 2017-08-29 | 刘荣惠 | 一种回春甘露补酒的配方及其制备方法 |
| KR101938865B1 (ko) * | 2016-11-03 | 2019-01-16 | 주식회사 쎌바이오텍 | 골 질환, 비만 및 지질 관련 대사성 질환의 예방 또는 치료용 조성물 |
| US11419882B2 (en) | 2017-06-08 | 2022-08-23 | Allergyintellect, Inc | Vitamin D compounds and methods of using the same |
| CN108342340B (zh) * | 2018-01-30 | 2021-03-23 | 华中农业大学 | 一种产细菌素的凝结芽孢杆菌及其制备方法和应用 |
| KR102362968B1 (ko) * | 2019-11-25 | 2022-02-17 | 주식회사 쎌바이오텍 | 유산균 및 프리바이오틱스를 포함하는 갱년기 증상의 예방, 완화 또는 치료용 조성물 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4110477A (en) * | 1977-05-13 | 1978-08-29 | Kabushiki Kaisha Naruse Fermentation Laboratory | Method for producing natto containing lactic acid bacteria |
| US4220660A (en) | 1977-12-14 | 1980-09-02 | Asta-werke Aktiengesellschaft, Chemische Farik | Process for the treatment of humans suffering from undesired urotoxic side effects caused by cytostatically active alkylating agents |
| USRE40792E1 (en) | 1992-05-19 | 2009-06-23 | Novogen Research Pty Ltd | Health supplements containing phyto-oestrogens, analogues or metabolites thereof |
| EP0693927A4 (de) | 1993-04-16 | 1997-05-28 | Univ Tufts Med | Verfahren zur behandlung menopausaler und prämentrueller symptome |
| US6344217B1 (en) * | 1994-06-28 | 2002-02-05 | Aar Pharma Adler Apotheke | Putamen OVI |
| US5516528A (en) | 1995-01-13 | 1996-05-14 | Wake Forest University | Dietary phytoestrogen in estrogen replacement therapy |
| JP3489930B2 (ja) * | 1996-03-08 | 2004-01-26 | 株式会社ヤクルト本社 | がん予防食品 |
| US6033714A (en) | 1996-03-13 | 2000-03-07 | Archer Daniels Midland Company | Process for production of isoflavone fractions from soy |
| US6261565B1 (en) | 1996-03-13 | 2001-07-17 | Archer Daniels Midland Company | Method of preparing and using isoflavones |
| US5702752A (en) | 1996-03-13 | 1997-12-30 | Archer Daniels Midland Company | Production of isoflavone enriched fractions from soy protein extracts |
| US6171638B1 (en) | 1996-03-13 | 2001-01-09 | Archer Daniels Midland Company | Production of isoflavone enriched fractions from soy protein extracts |
| AU6763198A (en) | 1997-03-24 | 1998-10-20 | Viva America Marketing, Inc. | Stabilized solid bacteria compositions |
| US6716424B1 (en) * | 1997-08-08 | 2004-04-06 | Otsuka Pharmaceutical Co., Ltd. | Streptococcus and isoflavone-containing composition |
| US6150399A (en) | 1998-06-30 | 2000-11-21 | Abbott Laboratories | Soy-based nutritional products |
| US6447809B1 (en) * | 1999-05-11 | 2002-09-10 | Metagenics, Inc. | Composition for promoting healthy bone structure |
| US6375994B1 (en) * | 1999-08-20 | 2002-04-23 | Sun Ten Laboratories, Inc. | Preparation of fiber, L-glutamine and a soy derivative for the purpose of enhancement of isoflavone bioavailability |
| JP2001333692A (ja) | 2000-05-25 | 2001-12-04 | Yakult Honsha Co Ltd | 発酵豆乳の製造方法 |
| JP4354611B2 (ja) * | 2000-05-31 | 2009-10-28 | 株式会社ヤクルト本社 | イソフラボンアグリコンを含む発酵豆乳およびその製造方法 |
| FR2813790B1 (fr) | 2000-09-11 | 2004-03-12 | Dolisos Lab | Preparations pharmaceutiques contenant des extraits d'isoflavone de soja et des micro-organismes probiotiques |
| US20020182274A1 (en) | 2001-03-21 | 2002-12-05 | Kung-Ming Lu | Methods for inhibiting cancer growth, reducing infection and promoting general health with a fermented soy extract |
| US6790462B2 (en) * | 2001-08-09 | 2004-09-14 | Rhodia Inc. | Calcium dietary supplement |
-
2003
- 2003-05-30 US US10/448,405 patent/US7025998B2/en not_active Expired - Lifetime
-
2004
- 2004-05-28 ES ES04012697T patent/ES2279995T3/es not_active Expired - Lifetime
- 2004-05-28 EP EP04012697A patent/EP1481676B1/de not_active Expired - Lifetime
- 2004-05-28 PT PT04012697T patent/PT1481676E/pt unknown
- 2004-05-28 DE DE602004003859T patent/DE602004003859T2/de not_active Expired - Lifetime
- 2004-05-28 AT AT04012697T patent/ATE349208T1/de not_active IP Right Cessation
- 2004-11-29 TW TW093136726A patent/TW200616653A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US7025998B2 (en) | 2006-04-11 |
| DE602004003859T2 (de) | 2007-06-21 |
| TW200616653A (en) | 2006-06-01 |
| EP1481676A1 (de) | 2004-12-01 |
| DE602004003859D1 (de) | 2007-02-08 |
| PT1481676E (pt) | 2007-01-31 |
| EP1481676B1 (de) | 2006-12-27 |
| US20040241260A1 (en) | 2004-12-02 |
| ES2279995T3 (es) | 2007-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602004003859D1 (de) | Phytoestrogene und Probiotikum für die weibliche Gesundheit | |
| King | Daidzein conjugates are more bioavailable than genistein conjugates in rats | |
| Gu et al. | Metabolic phenotype of isoflavones differ among female rats, pigs, monkeys, and women | |
| ISHIDA et al. | Preventive effects of the plant isoflavones, daidzin and genistin, on bone loss in ovariectomized rats fed a calcium-deficient diet | |
| US20110236358A1 (en) | Composition comprising isoflavones | |
| US20030219499A1 (en) | Therapy of estrogen-associated disorders | |
| Gustafsson et al. | Biogenesis of histamine studied by its distribution and urinary excretion in germ free reared and not germ free rats fed a histamine free diet. | |
| Tousen et al. | Resistant starch promotes equol production and inhibits tibial bone loss in ovariectomized mice treated with daidzein | |
| Tousen et al. | The combined effects of soya isoflavones and resistant starch on equol production and trabecular bone loss in ovariectomised mice | |
| ES2721848T3 (es) | Probióticos para su uso en la prevención primaria de enfermedades atópicas | |
| CN118620804B (zh) | 一种植物乳杆菌及其在修复盆底肌、保养皮肤中的应用 | |
| Tousen et al. | Effects of dietary fibre and tea catechin, ingredients of the Japanese diet, on equol production and bone mineral density in isoflavone-treated ovariectomised mice | |
| PL378435A1 (pl) | Nowe szczepy Bifidobacterium zdolne do wytwarzania glutaminy | |
| CN101797269A (zh) | 一种调节女性阴道微生态的生理平衡液 | |
| US20020114786A1 (en) | Pharmaceutical preparations comprising soybean isoflavone extracts and probiotic microogranisms | |
| WO2007013547A1 (ja) | 更年期障害予防・改善剤および機能性飲食品 | |
| CN111632073A (zh) | 一种抗菌消炎的女性私密益生菌组合物及其制备 | |
| RUENIS et al. | Effects of caffeine and theophylline on the development of dental caries in rats | |
| KR20130083692A (ko) | 대두배아 발효물을 포함하는 갱년기 증상 개선용 음료 조성물 및 그 제조 방법 | |
| KR101470282B1 (ko) | 소금 및 당의 조합물을 유효성분으로 함유하는 질이완증 또는 질건조증 예방 및 치료용 약학 조성물 및 이의 용도 | |
| CN108785383A (zh) | 一种抗菌妇科外用药物组合物及其制备方法与应用 | |
| Jacobi | The Intestinal diseases of infancy and childhood v. 2 | |
| Rowe et al. | Animal safety report on intravaginal progesterone controlled internal drug releasing devices in sheep and goats. | |
| WO2013050930A1 (en) | Development of a red clover phytoestrogen product for the prevention or treatment of osteoporosis | |
| KR100797557B1 (ko) | 생식기 염증 예방 또는 치료용 약제학적 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |